Thrombin antithrombin complex concentration as an early predictor of deep vein thrombosis after total hip arthroplasty and total knee arthroplasty

Zhencan Lin1,2†, Hao Sun1†, Deng Li1, Zhiqing Cai1, Meiyi Chen1, Wenhui Zhang1, Fangzhou Liu1, Zhencheng Huang1,2, Yimin Wang2, Jie Xu1* and Ruofan Ma1*

Abstract

Aim: Early predictive markers of venous thromboembolism (VTE) after total hip arthroplasty (THA)/total knee arthroplasty (TKA) remain unclear. Our study identified early predictive markers for VTE after THA/TKA.

Methods: A single-institution retrospective review study was conducted between May 2020 and April 2022 (n = 256). All patients underwent Doppler ultrasound exams in preoperation and seventh day after surgery. Deep vein thrombosis (DVT) was defined by Doppler ultrasound of the lower extremities, which revealed thrombosis. Thrombin-antithrombin complex (TAT), thrombomodulin (TM), and plasmin-antiplasmin complex (PIC) concentration were tested from each patient’s preoperative and postoperative days 1, 4, 7, 14. These values were then accessed via receiver operating characteristic (ROC) curve analysis and further quantified the level of this risk by concentration.

Results: On postoperative day 1 (pod-1), all patients’ TAT and PIC concentrations were significantly higher than those preoperatively (p < 0.05). The levels of TAT and PIC in patients in the DVT group on pod-1 were significantly higher than those in the non-DVT group (p < 0.05). At pod-1, the TAT concentration for DVT patients was 49.47 ng/mL compared to 20.70 ng/mL for non-DVT patients, PIC was 3.72μg/mL compared to 1.65μg/mL. ROC curve analysis demonstrated that a TAT concentration of 24.3 ng/mL had a sensitivity of 87.9% and a specificity of 69.1%.

Conclusion: TAT levels on pod-1 may predict DVT early after THA/TKA, which makes it possible for early intervention to decrease the incidence of DVT.

Keywords: Total hip arthroplasty, Total knee arthroplasty, Deep vein thrombosis

Introduction

Venous thromboembolism (VTE) is a common complication associated with total knee arthroplasty (TKA) and total hip arthroplasty (THA) [1]. At least 14 days of anticoagulant prophylaxis and the best duration of approximately 35 days were needed in patients undergoing THA/TKA [2]. VTE includes deep vein thrombosis (DVT) and pulmonary embolism (PE) [3]. PE may become a fatal, life-threatening complication. In the presence of thromboprophylaxis, the rate of venous thromboembolism (VTE) in patients undergoing major orthopedic surgery has been reported. The rate of DVT occurs between 2.22 and 3.29%, PE occurs between 0.87 and 1.99%, and fatal PE occurs in 0.30% of cases.
in America and Europe [4, 5]. DVT occurs in 1.40%; PE occurs in 1.10% of cases in Asia [6, 7]. Despite the relatively low incidence of DVT, this result is because ultrasound was not routinely performed, only for symptomatic patients following major orthopedic surgery before hospital discharge [4]. In a routine ultrasound screening study, 26 patients (47%) had asymptomatic distal DVT after TKA [8], and 39 patients (9.6%) had asymptomatic DVT after THA [9]. Thus, asymptomatic DVT also needs to be identified early to avoid the development of PE.

Up to this date, there has been a lack of effective indicators or methods to predict or identify VTE earlier. Currently, either P-selectin, D-dimer, or thromboelastography (TEG) do not indicate the risk of thrombosis [10–14]. Similar findings were obtained (our unpublished results). Thus, finding a new reliable, affordable, and easily available method to predict DVT is urgently needed.

Recently, new coagulation-associated hematological tests have emerged, such as thrombomodulin (TM), thrombin-antithrombin complex (TAT), and plasmin-antiplasmin complex (PIC). TM is a transmembrane glycoprotein that is highly expressed in endothelial cells (ECs) [15]. Antithrombin, the most abundant natural anticoagulant, regulates coagulation by combining thrombin to form the TAT complex [16]. The PIC consists of plasmin and its main physiological inhibitor, α2-antiplasmin (α2-AP), which can inhibit the fibrinolysis effect [17]. However, these indicators have been less studied in THA/TKA to predict DVT risk early. This study aimed to attempt to apply these indicators to predict DVT early.

**Methods**

We conducted a retrospective review of THA/TKA performed between May 2020 and April 2022 in our hospital. All patients underwent Doppler ultrasounds exam in preoperation and seventh day after surgery. This study included a total of 256 patients, of whom 33 were diagnosed with DVT and 223 were not using ultrasound on postoperative day 7 (pod-7). All patients were treated with low molecular heparin (enoxaparin sodium) 0.4 mL through subcutaneous injection at 12h after the surgery. On pod-2, enoxaparin sodium was administered subcutaneously once daily at 0.4 mL before discharge. Patients were excluded if they had been diagnosed with DVT before surgery. Patients were also excluded if they had a malignant tumor, blood system disease, or hepatic dysfunction.

**Laboratory evaluations and diagnosis method**

Venous blood samples were collected before surgery and on pod-1, pod-4, pod-7, and pod-14. The levels of TM, TAT, and PIC were detected using a fully automatic chemiluminescence immune analyzer (Sysmex HISCL-5000). All patients underwent Doppler ultrasound of the lower extremities to diagnose or rule out DVT before surgery and pod-7. The two groups were divided into the non-DVT and DVT groups. The lower extremity deep veins studied included the external iliac vein, femoral vein, popliteal vein, posterior tibial vein, anterior tibial vein, peroneal vein, and muscular calf vein.

**Statistical analysis**

Statistical analysis was performed with SPSS statistics 25.0 (SPSS, version 25.0) and MedCalc Statistical Software. The non-parametric test was performed to compare the two groups. Receiver operating characteristic (ROC) curves were plotted, and the area under the curve (AUC) was calculated to assess the specificity and sensitivity of distinguishing patients with and without DVT.

**Results**

There were no significant differences between the two groups regarding age, sex, or body mass index (Table 1). For all cases, the values of TM, TAT, and PIC were not consistent during perioperative for all THA/TKA patients (Fig. 1). In our study, most of our patients were observed drastic activation of the clotting system after surgery for the TAT and PIC (Fig. 1). Statistically

| Table 1 Demographics |
|----------------------|
|                     | non-DVT, n=223 | DVT, n=33 |
| Age(y)              | 63.9          | 66.8      |
| Gender (female/male)| 172/51        | 28/5      |
| BMI (kg/m^2)        | 25.38         | 26.29     |
| Hip/Knee            | 119/104       | 7/26      |
| Diseases: OA/RA/AVN/DDH/others | 114/4/46/21/38 | 22/4/2/2/3 |

Abbreviations: BMI Body mass index, OA Osteoarthritis, RA Rheumatic arthritis, AVN Avascular necrosis, DDH Developmental dysplasia of the hip.
significant differences were found between preoperation and pod-1 in TAT and PIC. All of the others significant differences are based on statistical analyses shown in Fig. 1.

Consequently, we focus on the value of TAT and PIC on pod-1. To further assess these findings, we conducted subgroup analyses of DVT events. There were no statistically significant differences at any time point between the two groups for TM. The levels of TAT and PIC in patients in the DVT group on pod-1 were significantly higher than those in the non-DVT group ($p < 0.05$). The level of TAT in the DVT group on pod-4, 7 was significantly higher than that in the non-DVT group ($p < 0.05$) (Fig. 2). A significant statistical difference was found between the two groups, both TAT and PIC, at the same time only in pod-1. Thus, we chose TAT and PIC data in pod-1 for ROC analysis.

According to ROC analysis (Fig. 3, Table 2), on pod-1, the optimal TAT cut-off value for thrombosis was 24.3 ng/mL, AUC, 0.730 (95% CI, 0.633–0.827), with the highest Youden index (0.36), a sensitivity of 42.4% and a specificity of 93.7%. Further analysis revealed that the plot combining ROC (TAT and PIC) had a similar area (0.857) under the ROC curve and odds ratio (OR). At the same time, AUC differences between TAT and TAT/PIC did not show statistical significance.

**Discussion**

DVT remains serious and common clinical complication worldwide after THK/TKA [18, 19]. It involves three risk factors: venous stasis, vascular injury, and hypercoagulability [20]. THA/TKA surgery results in significant hematological changes, tourniquet use, and reduced perioperative mobility, which elevates the risk of DVT. Once the thrombus is formed, there will be some symptoms, such as lower limb pain and swelling. To make matters worse, a thrombus may cause fatal PE.

Currently, most available diagnostic tests, such as P-selectin, D-dimer, and TEG, cannot predict the risk of thrombosis after THA/TKA. Thomas et al. determined
that at 6 weeks after the operation, 92% of THA patients and 100% of TKA patients had serum D-dimer measurements higher than the institutional threshold (0.40 mg/mL) for a “positive” quantitative test; thus, D-dimer was not considered applicable to predict DVT event [10]. Shi et al. found that increased P-selectin levels were detected in the postoperative group. However, compared to the non-DVT group, there was no increase in the DVT group after THA [12]. Tareq et al. reported a statistically significant difference between VTE-positive and VTE-negative patients using TEG [13]. Thus, we attempted to find an economical, accurate, and simple way to predict the risk of thrombosis. In this study, we found a statistically significant difference between DVT patients and normal patients in TAT and PIC on pod-1. The ROC curve analysis showed that the levels of TAT on pod-1 may predict DVT early after THA/TKA.

In our study, the incidence rate of asymptomatic DVT was 12.89% (33/256). In the study by Vincent et al., the incidence of DVT was 12.8% after THA/TKA [21], similar to a study by Wu et al.; the rate was 9.6% [9]. These findings are consistent with our research. We found that TAT and PIC could sensitively reflect changes in coagulation status. TAT levels may be associated with VTE incidence [22]. Kobayashi et al. reported significant differences in the TAT levels between the DVT group and the normal group after medial opening-wedge high tibial osteotomy (OWHTO) [23]. Increasing levels of TAT may be an independent risk factor for VTE development in hospitalized Japanese patients receiving chemotherapy for malignancies [24]. However, currently, there are no studies regarding the use of TAT to predict DVT after THA/TKA. Moreover, none of the included studies were specific to the prediction of DVT early after THA/TKA. Our study found that the levels of TAT and PIC on pod-1 may be able to predict which patients progress to detectable DVT early after THA/TKA. More importantly, we need a higher sensitivity rather than specificity. Hence, it was indicated that merely using TAT was an independent prognostic marker and had a higher prognostic value compared with PIC. We established a cut-off value greater than 24.3 ng/mL for early prediction of a higher risk of thrombosis by ROC curve analysis, which is of great significance for the early prevention and treatment of DVT and reduce the incidence of PE during the periparative period.

To improve risk stratification, we stratified the data according to the concentration levels of TAT (Table 3).
Then, we calculated the positive predictive value (PPV) (positive = thrombosis) under stratification. The stratification of TAT has important clinical implications for predicting the risk of thrombosis. The TAT concentration on pod-1 correlated with the onset of DVT. According to the consequence, when TAT was > 30 ng/mL, the PPV was 0.3333. When TAT was >40 ng/mL, the PPV was 0.4500.

The stratified analysis for TAT showed that the TAT concentration increased as the risk of DVT increased. According to our health center's condition, when TAT ≥30 ng/mL, we should focus on pain and swelling in the affected limb or multiple screen venous ultrasound testing of the lower extremity to identify thrombotic events earlier.

There are some limitations to this study. First, this was a single-center, retrospective study. Second, the sample size of this study was relatively small. Thus, we will enlarge the sample size of our study for further research. Multi-center prospective studies and large sample clinical studies are needed to illustrate and predict DVT in the future.

In summary, this study demonstrated that TAT has a high sensitivity but low specificity for the prediction of DVT. These results suggest that the levels of TAT on pod-1 may predict the occurrence of DVT. This study indicated that single indicator prediction was not inferior to combined indicators. Compared to other methods, a single indicator and single time point detecting TAT to predict DVT is simple, convenient, accurate, and effective.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

ZCL Conception and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript. HS Conception and design, critical revision of the manuscript. DL Acquisition and curation of data. ZQC Acquisition and curation of data. MYC Analysis and interpretation of data. WHZ Acquisition and curation of data. FZL Acquisition and curation of data. ZCH Acquisition and curation of data. YMW Final approval of the version, agree to be accountable for all aspects of the work. JX Final approval of the version, agree to be accountable for all aspects of the work. RFM Final approval of the version, agree to be accountable for all aspects of the work. All authors have read and approved the manuscript.

**Funding**

This study was funded by the The National Key R&D Program of China (No.2021YFA1102600), National Natural Science Foundation of China (No. 82002293), Science and Technology Planning Project of Guangzhou City, China (Grant No. 201803010011), Guangdong Basic and Applied Basic Research Foundation (Grant No. 2019A1515011647, 2021A1515010693, 2021A1515010294, 2022A1515010256).

**Availability of data and materials**

The data are available for download at https://figshare.com/articles/dataset/Untitled_Item/17119088.

**Declarations**

**Ethics approval and consent to participate**

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study and the subject described in this report. Protocol approved by the Ethical Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University.

**Consent for publication**

Not applicable.

**Competing interests**

On behalf of all authors, the corresponding author states that there is no conflict of interest.

**Author details**

1. Department of Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong, China. 2. Department of Orthopedics, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518000, Guangdong, China.

**Received:** 19 November 2021  **Accepted:** 6 June 2022  **Published online:** 14 June 2022

**References**

1. Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018;378(8):699. https://doi.org/10.1056/NEJMoa1712746.
2. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S. https://doi.org/10.1378/chest.11-2404.

3. Wen S, Duan Q, Yang F, Li G, Wang L. Early diagnosis of venous thromboembolism as a clinical primary symptom of occult cancer: Core proteins of a venous thrombus. OncoLett. 2017;14(1):491. https://doi.org/10.3892/ol.2017.6175.

4. Akpınar EE, et al. Does thromboprophylaxis prevent venous thromboembolism after major orthopedic surgery? J Bone Joint Surg. 2013;95(3):280–6. https://10.1095/1508-37132013000004.

5. Dixon J, Ahn E, Zhou L, Lim R, Simpson D, Merriman EG. Venous thromboembolism rates in patients undergoing major hip and knee joint surgery at Waitakere District Health board: a retrospective audit. Intern Med J. 2015;45(4):416. https://doi.org/10.1111/imj.12702.

6. Cha SI, Lee SY, Kim CH, Park JY, Jung TH, Yi JH. Venous thromboembolism in Korean patients undergoing major orthopedic surgery: a prospective observational study using computed tomographic (CT) pulmonary angiography and indirect CT venography. J Korean Med Sci. 2010;25(1):28. https://doi.org/10.3346/jkms.2010.25.1.28.

7. Leizorovicz A, Turpe AG, Cohen AT, Wong L, Yoo MC. Dans a SMART study group. Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART study. J Thromb Haemost. 2005;3:28–34. https://doi.org/10.1111/j.1538-7836.2004.01094.x.

8. Mitani G, Takagaki T, Hamahashi K, Serigano K, Nakamura Y, Sato M. Associations between venous thromboembolism onset, D-dimer, and soluble fibrin monomer complex after total knee arthroplasty. J Orthop Surg Res. 2015;10:172. https://doi.org/10.1186/s13018-015-0315-4.

9. Wu JX, Qiu JH, Yao Y, Chen DY, Jiang Q. Performance of age-adjusted D-dimer values for predicting DVT before the knee and hip arthroplasty. J Orthop Surg Res. 2021;16(1):82. https://doi.org/10.1186/s13018-020-02117-w.

10. An TJ, Engstrom SM, Oelsen WK, Bervenuta MA, Polkowski GG, Schoenecker JG. Elevated d-dimer is not predictive of symptomatic deep venous thrombosis after Total joint arthroplasty. J Arthroplast. 2016;31(10):2269. https://doi.org/10.1016/j.arth.2016.02.059.

11. Wu CT, Chen B, Wang JW, Yen SH, Huang CC. Plasma D-dimer is not useful in the prediction of deep vein thrombosis after total knee arthroplasty in patients using rivaroxaban for thromboprophylaxis. J Orthop Surg Res. 2018;13(1):173. https://doi.org/10.1186/s13018-018-0883-1.

12. Shi D, Xu X, Xu Z, Nakamura T, Pang Y, Yao C. P-selectin: an unpredicted factor for deep vein thrombosis after total hip arthroplasty. Biomed Res Int. 2014;2014:783967. https://doi.org/10.1155/2014/783967.

13. Abu Assab T, Raveh-Brawer D, Abramowitz J, Naamad M, Ganzel C. The predictive value of Thromboelastogram in the evaluation of patients with suspected acute venous thromboembolism. Acta Haematol. 2014;133(3):272. https://doi.org/10.1159/000352348.

14. Parameswaran A, Krishnamoorthy VP, Oommen AT, Jasper A, Korula RJ, Nair SC. Is pre-operative assessment of coagulation profile with Thromboelastography and indirect CT venography. J Korean Med Sci. 2010;25(1):28. https://doi.org/10.1590/0140-6736(05)71880-8.

15. Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after Total hip and knee replacement: a systematic review and Meta-analysis of randomized clinical trials. JAMA Intern Med. 2020;180(3):376. https://doi.org/10.1001/jamainternmed.2019.6108.

16. Lundbech M, Krag AE, Christensen TD, Hvas AM. Thrombin generation, thrombin-antithrombin complex, and prothrombin fragment F1+2 as biomarkers for hypercoagulability in cancer patients. Thromb Res. 2020;186:80. https://doi.org/10.1016/j.thromres.2019.12.018.

17. Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci. 2011;68(5):785. https://doi.org/10.1007/s00018-010-0565-5.

18. Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2015;97(19):2013. https://doi.org/10.2106/JBJS.L.01328.

19. Kyrle P, Eichinger S. Deep vein thrombosis. Lancet. 2005;365(9465):1163.

20. An V, Levy XD, Walker PM, Bruce W. Thrombosis rates using aspirin and a compression device as multimodal prophylaxis for lower limb arthropathy in a screened population. J Clin Orthop Trauma. 2020;11(Suppl 2):S187–91. https://doi.org/10.1016/j.jcot.2018.10.007.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions